Zivo Bioscience (Zivo Bioscience) Risk Assessment

View and export this data going back to 2021. Start your Free Trial

What is Zivo Bioscience Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Zivo Bioscience is: No Data: Cannot be evaluated.

Competitive Comparison of Zivo Bioscience's Risk Assessment

For the Biotechnology subindustry, Zivo Bioscience's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zivo Bioscience's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zivo Bioscience's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Zivo Bioscience's Risk Assessment falls into.

Zivo Bioscience (OTCPK:ZIVO) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Zivo Bioscience Risk Assessment Related Terms

Thank you for viewing the detailed overview of Zivo Bioscience's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Zivo Bioscience (Zivo Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zivo Bioscience Inc (OTCPK:ZIVO) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

21 East Long Lake Road, Suite 100, Bloomfield Hills, MI, USA, 48304

Website

https://www.zivobioscience.com

Zivo Bioscience Inc is a research and development company operating in both the biotech and agtech sectors, with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company's pipeline candidates are; Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Human Food Ingredients, and Skin Health.

Executives

Alison A Cornell	director	210 CARNEGIE CENTER, PRINCETON NJ 08540
Christopher D. Maggiore	officer: CHIEF FINANCIAL OFFICER	4788 NOBLES POND DR. NW, CANTON OH 44718
Nola E Masterson	director	768 WEST CALIFORNIA WAY, WOODSIDE CA 94062
John Bernard Payne	director	9900 NE 114TH CIRCLE, VANCOUVER WA 98662
Strome Mezzanine Fund, Lp	10 percent owner	100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401
Keith Marchiando	officer: Chief Financial Officer	C/O ZIVO BIOSCIENCE, INC., 21 E. LONG LAKE ROAD, SUITE 100, BLOOMFIELD HILLS MI 48304
Mark E Strome	10 percent owner	100 WILSHIRE BLVD, 15TH FL, SANTA MONICA CA 90401
Strome Alpha Fund L P	10 percent owner	100 WILSHIRE BLVD SUITE 1750, SANTA MONICA CA 90401
Strome Investment Management Lp	10 percent owner	100 WILSHIRE BLVD, 15TH FLOOR, SANTA MONICA CA 90401
Strome Group, Inc.	10 percent owner	100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401
Hep Investments Llc	10 percent owner	2804 ORCHARD LAKE RD, STE 205, KEEGO HARBOR MI 48320
Rondeau Robert O Jr	director	70 WEST LONG LAKE RD, STE 119, TROY MI 48098
Thomas Kevin Cox	director	470 MICHGAMME LANE, LAKE FOREST IL 60045
Andrew A Dahl	officer: President, CEO	7 WEST SQUARE LAKE ROAD, STE 6165, BLOOMFIELD HILLS MI 48302
Brian W Young	other: See remarks below.	1800 NW CORPORATE BLVD, BOCA RATON FL 33431